1. 2019
  2. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact

    ERIC, the European Research Initiative on CLL, Baliakas, P., Jeromin, S., Iskas, M., Puiggros, A., Plevova, K., Nguyen-Khac, F., Davis, Z., Rigolin, G. M., Visentin, A., Xochelli, A., Delgado, J., Baran-Marszak, F., Stalika, E., Abrisqueta, P., Durechova, K., Papaioannou, G., Eclache, V., Dimou, M., Iliakis, T., & 23 othersCollado, R., Doubek, M., Calasanz, M. J., Ruiz-Xiville, N., Moreno, C., Jarosova, M., Leeksma, A. C., Panayiotidis, P., Podgornik, H., Cymbalista, F., Anagnostopoulos, A., Trentin, L., Stavroyianni, N., Davi, F., Ghia, P., Kater, A. P., Cuneo, A., Pospisilova, S., Espinet, B., Athanasiadou, A., Oscier, D., Haferlach, C. & Stamatopoulos, K., 1 Jan 2019, In: Blood. 133, 11, p. 1205-1216 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

    HOVON CLL study group, Kater, A. P., van Oers, M. H. J., van Norden, Y., van der Straten, L., Driessen, J., Posthuma, W. F. M., Schipperus, M., Chamuleau, M. E. D., Nijland, M., Doorduijn, J. K., van Gelder, M., Hoogendoorn, M., de Croon, F., Wittebol, S., Kerst, J. M., Marijt, E. W. A., Raymakers, R. A. P., Schaafsma, M. R., Dobber, J. A., & 2 othersKersting, S. & Levin, M-D., Jan 2019, In: Haematologica. 104, 1, p. 147-154 8 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Ibrutinib: searching for a partner drug

    Kater, A. P. & Brown, J. R., Jan 2019, In: lancet oncology. 20, 1, p. 3-5 3 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. Auto-immuuncytopenieën bij patiënten met chronische lymfatische leukemie: een beknopt overzicht met aanbevelingen voor de praktijk

    de Back, T., Kater, A. & Tonino, S. H., 2019, In: Nederlands tijdschrift voor hematologie. 11, p. 321-328

    Research output: Contribution to journalArticleProfessional

  6. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy

    van Bruggen, J. A. C., Martens, A. W. J., Fraietta, J. A., Hofland, T., Tonino, S. H., Eldering, E., Levin, M-D., Siska, P. J., Endstra, S., Rathmell, J. C., June, C. H., Porter, D. L., Melenhorst, J. J., Kater, A. P. & van der Windt, G. J. W., 2019, In: Blood. 134, 1, p. 44-58

    Research output: Contribution to journalArticleAcademicpeer-review

  7. Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes

    Hofland, T., de Weerdt, I., ter Burg, H., de Boer, R., Tannheimer, S., Tonino, S. H., Kater, A. P. & Eldering, E., 2019, In: Journal of immunology (Baltimore, Md.. 203, 8, p. 2100-2109

    Research output: Contribution to journalArticleAcademicpeer-review

  8. Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia

    Hofland, T., Eldering, E., Kater, A. P. & Tonino, S. H., 2019, In: International journal of molecular sciences. 20, 17

    Research output: Contribution to journalReview articleAcademicpeer-review

  9. Ibrutinib and venetoclax for first-line treatment of CLL

    Kater, A. P., Levin, M-D. & Niemann, C. U., 2019, In: New England journal of medicine. 381, 8, p. 788-789

    Research output: Contribution to journalComment/Letter to the editorAcademic

  10. 2018
  11. Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy

    van der Straten, L., Dinmohamed, A. G., Westerweel, P. E., Langerak, A. W., Riedl, J., Doorduijn, J. K., Kater, A. P. & Levin, M-D., Nov 2018, In: Leukemia & lymphoma. 59, 11, p. 2757-2761

    Research output: Contribution to journalArticleAcademicpeer-review

  12. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

    Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., Panizo, C., Shah, B., Davies, A., Eek, R., Dupuis, J., Jacobsen, E., Kater, A. P., Le Gouill, S., Oberic, L., Robak, T., & 9 othersCovey, T., Dua, R., Hamdy, A., Huang, X., Izumi, R., Patel, P., Rothbaum, W., Slatter, J. G. & Jurczak, W., 2018, In: Lancet. 391, 10121, p. 659-667

    Research output: Contribution to journalArticleAcademicpeer-review

Previous 1...4 5 6 7 8 9 10 11 ...20 Next

ID: 64520